Mira Pharmaceuticals, Inc. (MIRA): R&D Expense
$1.72M
Year ended 2025-12-31
$2.14M
Trailing 12 months to 2026-06-30
-9.9%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.72M | -48.0% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $3.31M | +110.1% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $1.57M | -33.1% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $2.35M | n/a | 2024-04-01, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Mira Pharmaceuticals, Inc. (MIRA) | 2025-12-31 | $1.72M | -48.0% |
| MetaVia Inc. (MTVA) | 2025-12-31 | $6.80M | -68.4% |
| Decoy Therapeutics Inc. (DCOY) | 2025-12-31 | $368.2K | -52.2% |
| Lantern Pharma Inc. (LTRN) | 2025-12-31 | $11.51M | -28.6% |
| NewcelX Ltd. (NCEL) | 2025-12-31 | $1.13M | +13.5% |
| Curanex Pharmaceuticals Inc (CURX) | 2025-12-31 | $2.99M | n/a |
| Revelation Biosciences, Inc. (REVB) | 2025-12-31 | $4.06M | +14.5% |
| Traws Pharma, Inc. (TRAW) | 2025-12-31 | $12.14M | -5.5% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | 2025-12-31 | $4.05M | +12.0% |
Compare MIRA, MTVA, DCOY, LTRN side by side · Screen every company in Pharmaceutical Preparations ↗